Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.36 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21913 | 0.86 | YTHDC1 (0.47) | YTHDC1YTHDF2PDPK1HTTCYP1A2 | |
| SCHEMBL10918759 | 0.85 | YTHDC1 (0.46) | YTHDC1YTHDF2PDPK1HTTCYP1A2 | |
| SCHEMBL6272986 | 0.85 | YTHDC1 (0.46) | YTHDC1YTHDF2PDPK1HTTCYP1A2 | |
| SCHEMBL30677338 | 0.76 | PDPK1 (0.33) | PDPK1HTTCYP1A2HIF1AROCK1 | |
| SCHEMBL11591791 | 0.76 | HTT (0.33) | HTTCYP1A2HIF1AROCK1LMNA | |
| SCHEMBL405822 | 0.76 | PDPK1 (0.34) | YTHDC1YTHDF2PDPK1HTTCYP1A2 | |
| SCHEMBL9116343 | 0.75 | HTT (0.32) | HTTCYP1A2HIF1ALMNA | |
| SCHEMBL22892194 | 0.75 | CSNK2A1 (0.33) | YTHDC1YTHDF2PDPK1HTTCYP1A2 | |
| SCHEMBL4242949 | 0.75 | EGFR (0.33) | HTTCYP1A2HIF1ALMNA | |
| SCHEMBL160073 | 0.75 | CYP3A4 (0.35) | HTTCYP1A2HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-116457356-A | A3 adenosine receptor agonists for use in medicine | 生物干预公司 | 2023-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ADORA3, ADORA2A, ADORA2B | YTHDC1 3854/4885YTHDF2 3387/4885PDPK1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.